From Wikipedia, the free encyclopedia
- The correct title of this article is deCODE Genetics. The initial letter is shown capitalized due to technical restrictions.
deCODE genetics, Inc. (Íslensk erfðagreining in Icelandic) NASDAQ: DCGN is a biopharmaceutical company based in Reykjavík, Iceland. The company was founded in 1996 to identify human genes associated with common diseases using population studies, and apply the knowledge gained to guide the development of candidate drugs. So far the company has isolated genes believed to be involved in cardiovascular disease,cancer and schizophrenia, among other diseases (The company's research concerning the latter is said to represent the first time a gene has been identified by two independent studies to be associated with schizophrenia[citation needed] ).
deCODE's approach to identifying genes, and in particular its attempt to set up an Icelandic Health Sector Database (HSD) containing the medical records and genealogical and genetic data of all Icelanders, has been very controversial, and prompted national and international criticism for its approach to the concepts of privacy and consent [1] A legal judgement from the Icelandic Supreme Court in November 2003 effectively killed off the HSD project [2]. However, the company believes it can continue to identify disease-related genes without such a database [3].
[edit] See also
